KalVista Pharmaceuticals faces a shrinking HAE market, tough competition, and launch uncertainty despite FDA approval. Read ...

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, KalVista ...

KalVista Pharmaceuticals, Inc. (KALV) on Monday said that the U.S. Food and Drug Administration (FDA) has approved its drug Ekterly for the treatment of acute attacks of hereditary angioedema in ...

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares ...

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...

KalVista on Friday said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use covers Ekterly in people ages 12 and older for the symptomatic treatment of ...

KalVista (NASDAQ: KALV) is a clinical-stage pharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing oral therapies for the rare disease hereditary angioedema (HAE).

BofA raised the firm’s price target on KalVista (KALV) to $37 from $22 and keeps a Buy rating on the shares after the company announced the approval of Ekterly for on-demand treatment of ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Mr. Piekos is an ex ...

KalVista Pharmaceuticals Inc. shares tumbled 47% in premarket trade Tuesday, after the company said it's halting a Phase 2 trial of a treatment for hereditary angioedema, after multiple patients ...

CAMBRIDGE, Mass.& SALISBURY, England---- KalVista Pharmaceuticals, Inc. today announced Marketing Authorization Application submissions to the regulatory authorities in the United Kingdom ...